Grant: Strategic Projects - Group
University of Toronto
$84,000.00
Implementing microfluidics-based manufacturing of model theranostic nanoparticles
FY 2013-14
Summary
Nanoparticles (NPs) are being exploited in the labeling of tissues and within cells for the detection and tracking of biological markers, chemical signals and dynamic cellular events. We have been contributing to the area of learning to build functional NPs for bioassays. We are now in a position to launch the next step of technology evolution where the bioanalytical detection system concurrently becomes a platform for delivery of a cargo such as a therapeutic agent. With our industry partner GL Chemtec, we will learn to manufacture such ""theranostic"" platforms, drawing on our joint strengths in synthesis at surfaces and in bioassay development.The impact of NPs in bioanalytical technology in the next 5-10 years will be determined by the ability to create new benchmarks in assembly of functional materials. We see a significant opportunity in the use of upconverting nanoparticles (UCNPs) as the basis of a NP technology that offers active sensing and cargo delivery. Upconversion is a process in which two or more photons are absorbed and combined, and because multiple photon absorptions occur sequentially rather than simultaneously, this eliminates the need for high power density pulsed lasers. Long wavelength excitation towards the infrared is more suitable for penetrating into biological samples and reducing background, and the upconversion process allows optical probing at a shorter wavelength for a bioassay, and concurrent excitation at even a shorter wavelength to trigger 'on demand' photocleavage for cargo delivery.The goal of this research is to develop a manufacturing process that will offer a new nanoparticle-based platform capable of bioassay and targeted cargo delivery. The two main themes of investigation are: 1. UCNPs synthesis defining upconversion wavelength channels, appropriate protective shells, and conjugation of chemistries for diagnostic capabilities, photo-labile cargo release chemistry, and cellular targeting.2. Implementation of a microfluidic reactor based on solid-phase synthetic modification of immobilized UCNPs to produce and to quantitatively collect the final theranostic platforms.
Program
Strategic Projects - Group
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
430530-2012
Name nom
Krull, Ulrich
Department département
Chemical and Physical Sciences (Mississauga)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2012
Award amount
84000
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1569
Committee name en
Strategic Projects Selection Panel - Manufacturing
Committee name fr
Comité de sélection des projets stratégiques - Fabrication
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
2006
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Biomaterials
Research subject fr
Biomatériaux
Partie
2
Nb partie
3
Application title
Implementing microfluidics-based manufacturing of model theranostic nanoparticles
Keyword
NSERC
Application summary
Nanoparticles (NPs) are being exploited in the labeling of tissues and within cells for the detection and tracking of biological markers, chemical signals and dynamic cellular events. We have been contributing to the area of learning to build functional NPs for bioassays. We are now in a position to launch the next step of technology evolution where the bioanalytical detection system concurrently becomes a platform for delivery of a cargo such as a therapeutic agent. With our industry partner GL Chemtec, we will learn to manufacture such ""theranostic"" platforms, drawing on our joint strengths in synthesis at surfaces and in bioassay development.The impact of NPs in bioanalytical technology in the next 5-10 years will be determined by the ability to create new benchmarks in assembly of functional materials. We see a significant opportunity in the use of upconverting nanoparticles (UCNPs) as the basis of a NP technology that offers active sensing and cargo delivery. Upconversion is a process in which two or more photons are absorbed and combined, and because multiple photon absorptions occur sequentially rather than simultaneously, this eliminates the need for high power density pulsed lasers. Long wavelength excitation towards the infrared is more suitable for penetrating into biological samples and reducing background, and the upconversion process allows optical probing at a shorter wavelength for a bioassay, and concurrent excitation at even a shorter wavelength to trigger 'on demand' photocleavage for cargo delivery.The goal of this research is to develop a manufacturing process that will offer a new nanoparticle-based platform capable of bioassay and targeted cargo delivery. The two main themes of investigation are: 1. UCNPs synthesis defining upconversion wavelength channels, appropriate protective shells, and conjugation of chemistries for diagnostic capabilities, photo-labile cargo release chemistry, and cellular targeting.2. Implementation of a microfluidic reactor based on solid-phase synthetic modification of immobilized UCNPs to produce and to quantitatively collect the final theranostic platforms.